StockIQpro
NASDAQ:LYEL

Lyell Immunopharma, Inc.

Track all markets on TradingView
Track all markets on TradingView

Lyell Immunopharma, Inc.'s revenue fell 41.0% in fiscal 2025 to $36,000 while operating margin fell to −748344.4%, its lowest in 7 years. Free cash flow was −$150.8M, −418900.0% of revenue, and the diluted share count rose 30.7%.Summary generated from Lyell Immunopharma, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$36,000
Revenue growth−41.0%
Revenue, 5-yr CAGR−65.9%
Gross marginn/a
Operating margin−748344.4%
Net margin−762355.6%
ROICn/a
Return on equity−87.0%
Debt / equityn/a
Free cash flow−$150.8M
FCF margin−418900.0%
Share count change+30.7%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue1185000
Operating income−215−187−247−359−269
Net income−250−183−235−343−274
Free cash flow−192−194−166−163−151

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations